Tweet
I should have held longer....
-
-
ELN baby, is there anyone alive out there ......Comment
-
The King is Back !!! He never was forgotten, especially when the ELN ticker crossed the screen.
----------billyjoeComment
-
-
-
Originally posted by kingofthehill View Post
Geez...where the heck you been King???
Nice move...Someday this outfit might even make money
BTW...Just missed making My Today's MoMo List because the RS is only 95 and I require an RS of 96-100...Maybe tomorrow"Trade What Is Happening...Not What You Think Is Gonna Happen"
Find Tomorrow's Winners At SharpTraders.com
Follow Me On TwitterComment
-
ELN moved on BIIB news that they just put themselves up for sale. And ELN partners with BIIB on Tysabre. That's all the fuss. And that is just rumor with no prospective partners in the hall waiting to pick up their date, BIIB.Originally posted by IIC View PostComment
-
Biogen bid has secured the survival of Elan
Tools
Print Email Search
Search
Go By Dan White
Sunday October 21 2007
AFTER almost six years of ducking and diving, Elan's long term future finally looks to have been secured.
Carl Icahn's bid for Biogen -- which jointly owns the MS drug Tysabri with Elan -- has put a floor under the Elan share price and allows investors to look again at its promising development pipeline.
Carl Icahn has bid $23bn for Biogen, which has responded by putting itself up for sale to the highest bidder. While Elan has the option of buying Biogen's half-share of Tysabri in the event of a change of control, it is far more likely to sell out to whoever ends up purchasing Biogen instead.
How much will Elan get for its half of Tysabri? Goodbody Stockbrokers has put a value of between $9.5bn and $14bn on the drug, which would value Elan's share at between $4.75bn and $7bn. If these estimates are correct then they put a floor of somewhere between $10 and $15 under the Elan share price.
Regardless of the final price, the likely sale of Tysabri secures Elan's long-term future. Ever since its shares lost 98 per cent of their value between June 2001 and July 2002, it has been touch and go as to whether the company would survive.
That question has now been answered emphatically. What investors now need to focus on is Elan's development pipeline. It has a number of promising new drugs in development, including treatments for both Alzheimer's and Parkinson's diseases. If either of these come good, then the sky is the limit for Elan. All of this means that, even at the current $23 price, Elan's shares no longer look expensive.
- Dan White
Comment
-
MS Drug Tysabri Approved for Crohn's Disease
01.14.08, 12:00 AM ET
MONDAY, Jan. 14 (HealthDay News) -- Tysabri, a controversial drug used to treat multiple sclerosis, may also be used for patients with a moderate to severe form of another autoimmune illness, Crohn's disease, the U.S. Food and Drug Administration announced Monday.
But the drug also comes with a rare but serious risk of a potentially deadly brain infection, as well as other side effects, so it must be used carefully, the FDA said in a press teleconference.
"With the addition of Tysabri to the treatment options of sufferers of Crohn's disease, we make an important step in the armamentarium for treatment, but one that carries serious risks," said Dr. Joyce Korvick, deputy director of the division of gastroenterology products at the FDA's Office of New Drugs.
Crohn's is a serious, often painful, inflammatory bowel disorder that affects about 600,000 people in the United States. It can involve intestinal bleeding, diarrhea, weight loss, arthritis, skin problems, fever and anemia.
Tysabri (natalizumab), a monoclonal antibody used to treat MS, has been under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS.
But the drug has a checkered past. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy (PML).
In June 2006, the FDA allowed the drug to return to the market but with strict conditions. According to the new guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program called CD Touch, designed by Biogen Idec, the maker of Tysabri, and approved by the FDA.
Last August, an FDA advisory panel voted 12-3 in favor of the use of the drug for Crohn's disease during a joint meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
At the time, the panel found that Tysabri could help ease the symptoms of the disease in patients who don't respond to standard therapies such as steroids or immunosuppressants.
The FDA is only approving Tysabri for Crohn's patients with moderate to severe symptoms, and this use will be subject to strict controls.
Korvick said that, besides the risk of PML, Tysabri also raises a patient's odds for hypersensitivity reactions, liver injury and severe herpes infections, especially in those on immunosuppressant therapy, so people taking immuno-suppressing drugs should not take Tysabri, Korvick said.
Crohn's patients who begin Tysabri therapy should also taper off their use of steroids, she added.
Side effects from the drug include headache, fatigue, infusion reactions, rash, and joint and limb pain.
"Because of these risks, patients, prescribers, pharmacies and infusion centers must all be enrolled in the [drug makers'] 'CD Touch' program and agree to comply with the company's strict monitoring guidelines," Korvick said. Doctors should also "evaluate Crohn's patients after three months of treatment to determine if they have improved on Tysabri. If not, then patients should be discontinued," she added.
According to the Wall Street Journal, Biogen Idec earlier this month noted that more than 21,000 patients were using Tysabri without any additional reports of PML.
More informationComment
-
FDA Approves Tysabri for Chron's disease
From marketwatch.com:
SAN FRANCISCO (MarketWatch) -- Elan Corp. (ELN:Elan Corporation, plc ELN 24.89, +0.13, +0.5%) and Biogen Idec Inc. (BIIB:biogen idec inc com BIIB 59.98, +0.96, +1.6%) said Monday that the Food and Drug Administration approved the multiple sclerosis drug Tysabri to treat Crohn's disease, a serious inflammation of the small intestine. Elan, an Irish pharmaceutical company, and Biogen Idec, a Cambridge, Mass.-based biopharmaceutical company, anticipate Tysabri will be available to Crohn's patients by the end of February.Comment
-
YES i still own that HEARTBREAKER ELN
Comment
-
Webs, are you still holding ELN? I recall you buying up some in the $9 areaComment
-
Spike - give me your reading on ELN , PleaseComment
-
Comment